cadenas

Innovative Therapies for Children with Cancer in Europe

  • Innovative Therapies
    for Children with Cancer in Europe
  • Contact us

Innovative Therapies for Children with Cancer

  • A phase IB/II open label study of the MEK-inhibitor selumetinib in combination with dexamethasone for paediatric and adolescent patients with ≥2nd relapsed precursor B or T ALL

  • Phase II trial of nivolumab for pediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with PD or as consolidative immunotherapy in patients in CR after relapse

  • Multicentre, open label, single arm Phase II study of Pegylated recombinant human arginase (BCT-100) in children > 1 year and <18 years with solid tumours, CNS malignancies and leukemias that are recurrent or refractory to standard therapy

  • T2015-001 A phase I study of Inotuzumab Ozogamycin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia

  • A phase I/II study of Bosutinib in pediatric patients with Chronic Myeloid Leukemia who are resistant or intolerant to at least one prior Tyrosine Kinase Inhibitor therapy

  • A phase I/II, multi-center, dose-escalating study to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of Quizartinib administered in combination with re-induction chemotherapy, and as a single-agent maintenance therapy

  • An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects ≥1 and ≤30 Years of Age with Relapsed/Refractory Precursor B-cell or T cell Acute Lymphoblastic Leukemia

  • A PHASE I/II, MULTICENTER, OPEN-LABEL, MULTI-ARM STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF IDASANUTLIN